In a Christmas scare at Perrigo, the drugmaker’s shares fell to a new low since around late 2009 after the company unveiled that it might owe the Irish government a large tax bill. As the appeal process could take years,
read moreAlexion was expecting a decision on its Soliris successor by February, but thanks to a quick review from U.S. regulators, it’s made its way onto 2018’s list of new drug approvals. More: FDA gifts Alexion quick OK for Soliris follow-up
read moreBack in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. More: Pfizer, Merck KGaA's Bavencio takes a hit with second ovarian cancer failure
read moreAcorda has proved wrong those doubting it could pull off a crucial approval for Parkinson’s drug Inbrija. But that doesn’t mean the company is out of the woods. More: Battered Acorda pulls off delayed Parkinson’s approval for Inbrija Source: fierce
read moreThe National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending treatment for adults with advanced liver cancer. More: NICE recommends Lenvima for advanced liver cancer Source: News
read moreResearchers at Imperial and Bayer Pharmaceuticals are partnering up to explore how artificial intelligence (AI) can be used to accelerate the discovery of new drugs for heart conditions. More: Imperial and Bayer to use AI for heart conditions Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals